Table 2.

DAS28(CRP) and ACR response rates at weeks 20 and 32

	Certolizumab pegol–IR plus bimekizumab (n=52)	Certolizumab pegol–IR plus placebo (n=27)
DAS28(CRP) <3.2, n (%)
Week 20	21 (45.7)	7 (29.2)
Week 32	26 (60.5)	11 (47.8)
ACR20, n (%)
Week 20	26 (60.5)	13 (54.2)
Week 32	25 (62.5)	15 (65.2)
ACR50, n (%)
Week 20	15 (34.9)	2 (8.3)
Week 32	16 (40.0)	6 (26.1)
ACR70, n (%)
Week 20	6 (14.0)	0
Week 32	11 (27.5)	5 (21.7)

ACR20, ACR50, ACR70, American College of Rheumatology 20%, 50% and 70% improvement criteria.

DAS28(CRP), Disease Activity Score 28-joint count (C-reactive protein).